昊海生科拟购买瑞济生物19.8%股权

Core Viewpoint - The company Haohai Biological Technology (688366.SH) plans to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.35 million, enhancing its presence in the high-value medical device sector focused on biological amniotic membranes [1] Group 1: Company Acquisition - Haohai Biological Technology will use its own funds to acquire 8.4661 million shares from shareholders Miao Jiuchang and Miao Chunyu [1] - The acquisition allows Haohai to gain distribution rights for Ruiji's products within China, thereby expanding its product portfolio in the ophthalmology and orthopedics fields [1] Group 2: Business Overview of Ruiji - Ruiji Biological was established in 2002 and specializes in the production and sale of biological amniotic membranes, which are classified as Class III medical devices [1] - The main products include convex and concave amniotic membranes, biological orthopedic amniotic membranes, and wet biological amniotic membranes, used primarily in orthopedic and ophthalmic applications [1] Group 3: Strategic Implications - The acquisition is expected to provide important technical and material foundations for Haohai's research and development in regenerative medicine and tissue engineering [1] - The human-derived biological characteristics of the amniotic materials are anticipated to drive innovation and technological upgrades in subsequent product offerings [1]